Back

StatPearls, LLC

  • Anti-Anxiety Agents
  • Antidepressive Agents
  • Antiemetics
  • Emetics
  • Neurokinin-1 Receptor Antagonists

Antiemetic Neurokinin-1 Receptor Blockers

Neurokinin-1 (NK-1) receptor antagonists are antiemetic drugs with unique anxiolytic, antidepressant, and antiemetic properties. The discovery of NK-1 receptor blockers was crucial in preventing emesis associated with cancer chemotherapy. The NK-1 receptor antagonist competitively binds to the NK-1 receptor, thereby blocking the binding of substance P and preventing the transmission of the emetic signal. This activity reviews the indications, contraindications, mechanism of action, adverse event profile, and other crucial aspects of antiemetic NK-1 receptor blockers within the clinical setting. This activity also focuses on essential information required by members of an interprofessional team responsible for treating patients who stand to benefit therapeutically from these agents.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1.5 creditsAAPA Category 1 Credit™Up to 1.5 creditsAMA PRA Category 1 Credit™Up to 1.5 creditsNursingUp to 1.5 creditsPharmacyUp to 1.5 credits

MOC types

ABS — Accredited CMEUp to 1.5 pointsABPATH — Lifelong LearningUp to 1.5 pointsABA — Lifelong LearningUp to 1.5 pointsABTS — Accredited CMEUp to 1.5 pointsABIM — Medical KnowledgeUp to 1.5 pointsABS — Self-AssessmentUp to 1.5 pointsABP — Lifelong Learning and Self-AssessmentUp to 1.5 pointsABOHNS — Self-AssessmentUp to 1.5 pointsABTS — Self-AssessmentUp to 1.5 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 11 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1.5 credits
  • MOC · Up to 1.5 points
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left